Citation: Carman K.M. Ip, Jun Yin, Patrick K.S. Ng, Shiaw-Yih Lin, Gordon B. Mills. Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management[J]. AIMS Medical Science, 2016, 3(4): 386-416. doi: 10.3934/medsci.2016.4.386
| [1] | Afraa Said Al-Adawi, Christine C. Gaylarde, Jan Sunner, Iwona B. Beech . Transfer of bacteria between stainless steel and chicken meat: A CLSM and DGGE study of biofilms. AIMS Microbiology, 2016, 2(3): 340-358. doi: 10.3934/microbiol.2016.3.340 |
| [2] | Aynur Aybey, Elif Demirkan . Inhibition of Pseudomonas aeruginosa biofilm formation and motilities by human serum paraoxonase (hPON1). AIMS Microbiology, 2016, 2(4): 388-401. doi: 10.3934/microbiol.2016.4.388 |
| [3] | Almaris N. Alonso . Hydrophobic nature and effects of culture conditions on biofilm formation by the cellulolytic actinomycete Thermobifida fusca. AIMS Microbiology, 2015, 1(1): 1-10. doi: 10.3934/microbiol.2015.1.1 |
| [4] | Joseph O. Falkinham . Mycobacterium avium complex: Adherence as a way of life. AIMS Microbiology, 2018, 4(3): 428-438. doi: 10.3934/microbiol.2018.3.428 |
| [5] | Yunfeng Xu, Attila Nagy, Gary R. Bauchan, Xiaodong Xia, Xiangwu Nou . Enhanced biofilm formation in dual-species culture of Listeria monocytogenes and Ralstonia insidiosa. AIMS Microbiology, 2017, 3(4): 774-783. doi: 10.3934/microbiol.2017.4.774 |
| [6] | Luciana C. Gomes, Joana M. R. Moreira, José D. P. Araújo, Filipe J. Mergulhão . Surface conditioning with Escherichia coli cell wall components can reduce biofilm formation by decreasing initial adhesion. AIMS Microbiology, 2017, 3(3): 613-628. doi: 10.3934/microbiol.2017.3.613 |
| [7] | Stephen H. Kasper, Ryan Hart, Magnus Bergkvist, Rabi A. Musah, Nathaniel C. Cady . Zein nanocapsules as a tool for surface passivation, drug delivery and biofilm prevention. AIMS Microbiology, 2016, 2(4): 422-433. doi: 10.3934/microbiol.2016.4.422 |
| [8] | Kamila Tomoko Yuyama, Thaís Souto Paula da Costa Neves, Marina Torquato Memória, Iago Toledo Tartuci, Wolf-Rainer Abraham . Aurantiogliocladin inhibits biofilm formation at subtoxic concentrations. AIMS Microbiology, 2017, 3(1): 50-60. doi: 10.3934/microbiol.2017.1.50 |
| [9] | Yusuke Morita, Mai Okumura, Issay Narumi, Hiromi Nishida . Sensitivity of Deinococcus grandis rodZ deletion mutant to calcium ions results in enhanced spheroplast size. AIMS Microbiology, 2019, 5(2): 176-185. doi: 10.3934/microbiol.2019.2.176 |
| [10] | Jonathan K. Wallis, Volker Krömker, Jan-Hendrik Paduch . Biofilm formation and adhesion to bovine udder epithelium of potentially probiotic lactic acid bacteria. AIMS Microbiology, 2018, 4(2): 209-224. doi: 10.3934/microbiol.2018.2.209 |
Opportunistic bacteria Cutibacterium (formerly Propionibacterium) acnes [1] are a member of the normal human skin and mucous membranes' microbiota [2]. However, C. acnes are increasingly recognized as a pathogen, mainly in foreign-body infections, such as arthroplasty or spinal instrumentation-associated infections [3,4]. The biofilm formation of C. acnes are often implicated as a cause of infection following the implantation of joint prostheses, in particular, a shoulder joint [5], intervertebral discs [6,7], breast prostheses [8] and heart valves [9].
Comparing the places of the most frequent detection of C. acnes biofilm, for example, with S. aureus which often forms the biofilm on stents, intravenous catheters, central line and etc. [10] it seems that C. acnes prefer an environment where the conditions are close to anaerobic and there is no bloodstream. However, only a few studies have provided data on the influence of blood components, especially plasma, on C. acnes biofilm formation. Holmberg et al. reported that C. acnes primarily infect plasma-poor environments, for example, joint prostheses and cerebrospinal shunts due to an inhibitory action of plasma on the biofilm formation of C. acnes [11]. While Bayston et al. claimed that the presence of a plasma conditioning film did not make a significant difference to C. acnes adhesion [12]. Thus, the effects of protein-coated surfaces on the adhesion of C. acnes remain unclear.
A multitude of proteins are present in human plasma and hence adsorb to the surface of a biomaterial upon blood contact with the formation of so called “conditioning film”. This film plays a major role in determining the interaction of bacteria with biomaterial surfaces. As previous studies have shown this film promotes or inhibits bacterial adhesion. For example, human plasma is responsible for the reduction of Staphylococcus epidermidis adhesion and biofilm formation on polyurethane due to the nonspecific interaction and the significant decrease in hydrophobicity [13]. In addition to the conditioning film the plasma proteins are able to interact directly with the surface of bacterial cells [14].
In addition, the influence of plasma on the biofilm formation of pathogenic bacteria is may be also associated with metal ions such as calcium and magnesium, and occasionally zinc [15,16,17]. Moreover, the bacterial capacity to agglutinate erythrocytes as well as biofilm formation is most frequently studied virulence factor [18]. The bacterial ability to directly bind to red blood cells allows them spread in the bloodstream [19]. Unfortunately, the possibility of C. acnes to interact with erythrocytes has been poorly studied.
The aim of this study was to examine the role of the plasma, serum and albumin, as well as calcium, magnesium, and zinc in the adhesion mechanism of C. acnes.
The type bacterial strain C. acnes ATCC®6919 (received as P. acnes VKM Ac-1450 from All-Russian Collection of Microorganisms, Pushchino, Russia) was used in this study. Bacteria from an overnight incubation at 37 °C in Luria-Bertani (LB) broth (10 g tryptone, 5 g yeast extract, 6.4 g KCl and Milli-Q water to 1l; Sigma-Aldrich) were harvested by centrifugation (13,000 rpm, 5 min), washed twice with 0.85% NаCl and diluted to 5 × 107 CFU/ml in LB medium.
Human whole plasma was prepared from blood drawn by venapuncture from three healthy donors. Blood was collected in vacuum tubes with EDTA (Improvacuter, China) and centrifuged (4,000 rpm, 5 min), and the supernatant was diluted in 10 times by 0.85% NaCl or LB medium. To study the effect of simultaneous presence of C. acnes cells and blood proteins on adhesion and biofilm formation the LB medium containing either 10% (v/v) plasma, 10% (v/v) heat inactivated fetal bovine serum (Biolot, Russia), or 5 mg/ml bovine serum albumin (Sigma-Aldrich, USA) was used. The medium supplemented with 0.85% NaCl was used as the control.
To examine the role of divalent metal ions on C. acnes adhesion and biofilm formation the LB medium supplemented with 0.1, 1 or 10 mM of ZnCl2, CaCl2 or MgCl2 was used. The LB medium was used as the control.
To investigate the influence of proteins on C. acnes adhesion and biofilm formation human plasma (10%), heat inactivated fetal bovine serum (10%) and bovine serum albumin (5 mg/ml) were pre-adsorbed to the polystyrene surface for 24 h prior to the bacterial adhesion or the biofilm formation assay. The control group for protein-coated surfaces was incubated in 0.85% NaCl without proteins.
Bacterial adhesion was studied in static conditions in protein-coated or untreated 40 mm polystyrene Petri dishes. For this, C. acnes cells (2 ml/dish) allowed adhering at 37 °C for 60 min. After the triple rinsing with PBS and the staining with 0.1% crystal violet the mean of the number of the adherent bacterial cells was counted at least in 10 field-of-view (FOV) for each dish using the digital optical microscope (µViso-103; Lomo, Russia) at magnification ×1000.
The biofilm formation of C. acnes was carried out according to the standard procedure in a 96-well flat-bottom polystyrene plate [20] with or without protein-coating (Medpolimer, Russia) in appropriate medium at 37 °C for 48 h. The biomass of the biofilm was determined as OD570 of the ethanol extract after dyeing with 0.1% crystal violet for 20 min using a microtiter plate reader (Benchmark PlusMicroplate Spectrophotometer System, Bio-Rad, USA).
The level of the adhesion of C. acnes to erythrocytes was accessed according to the method of Rupp & Archer [21]. Briefly, fresh human erythrocytes (blood type O, Rh+) were washed twice in PBS and diluted to 1% by PBS. Beforehand a series of two fold dilutions of C. acnes suspension starting from 108 CFU/ml in the 96-well round bottom plate was prepared. Then, the bacteria were mixed with equal amounts of erythrocytes (100 µl/well) and incubated for 2 h at room temperature. The level of hemagglutination was judged by the formation of a precipitate of erythrocytes in the well. The number of the adherent to erythrocytes bacterial cells was counted after dyeing with 0.1% crystal violet for 10 min at least for 100 erythrocytes using the digital optical microscope (µViso-103; Lomo, Russia) at magnification ×1000.
Statistical analysis of the data was carried out using the ANOVA method. The results were presented as M ± SD for three independent experiments. The differences at p < 0.05 were considered reliable.
Bacterial adhesion and biofilm formation of C. acnes ATCC 6919 on protein-coated and untreated polystyrene surfaces are shown in Figure 1. The bacterial adhesion significantly decreased when surface was coated with plasma, serum or albumin compared to untreated polystyrene (Figure 1A). The similar effect was observed when proteins were added to the medium simultaneously with bacterial cells. It is interesting to note that serum caused almost twice more pronounced inhibitory effect compared with plasma or albumin.
The inhibitory effect of blood proteins against C. acnes ATCC 6919 continued even after incubation for 48 h. As shown in Figure 1B the biomass of 2-day old biofilm of C. acnes ATCC 6919 on the protein-coated polystyrene was lower than control by 30%-60%. A similar situation was observed in the presence of proteins. So, C. acnes biofilm formation was about twice slower in LB medium supplemented with plasma, serum and albumin to compare the control (Figure 1B).
Figure 1. Adhesion (A) and biofilm formation (B) of C. acnes ATCC 6919 on polystyrene surface coated by or in the presence of 10% plasma, 10% serum and 0.5% albumin. The error bars indicate the standard deviations of the means for three experiments.Thus, the protein coating of the polystyrene surfaces reduced the amount of bacterial adhesion as well as the biofilm formation of C. acnes. Moreover, the attachment and biofilm formation of C. acnes in the presence of plasma, serum and albumin was quite also low. Hence, our results which show the significant influence of blood components on the C. acnes adhesion and biofilm formation are opposing to the results of Bayston et al. [12], but support the hypothesis of Holmberg et al. [11]. The mechanism of the inhibition of the bacterial attachment to plasma or albumin-coated polymeric surface is often related to the decrease in the surface hydrophobicity [13]. Whereas antibiofilm activity of human serum against S. epidermidis is associated with apo-Transferrin [22]. Although apo-Transferrin was found to suppress S. epidermidis biofilm production, it had no effect on S. epidermidis initial adhesion. Therefore, the inhibitory effect of serum on the first stages of biofilm formation is probably also mediated by albumin.
Additionally, C. acnes have 80 kDa surface-associated, fibronectin-binding protein [14], which could promote the bacterial adhesion on the plasma-coated surface, but in our experiments, we observed the opposite effect (Figure 1A). This effect may depend on the bacterial strain probably due to differences in bacterial cell surface properties.
However, as shown in earlier studies the bivalent metal ions, such as calcium and magnesium, also control the adhesive properties of bacterial cells, for example, staphylococci [15,16]. Therefore, we investigated the effect of Ca2+ and Mg2+ ions on the adhesion and biofilm formation of C. acnes in concentrations similar to their level in the serum (∼1 mM) and in 10 times lower and higher (0.1 mM and 10 mM, respectively). Despite the low concentration of zinc in the blood (0.1-0.2 mM) we also evaluated the effect of Zn2+ on the adhesion and biofilm formation of C. acnes due to the widespread use of zinc-containing drugs for the treatment of acne [23].
Bacteria C. acnes exhibited different abilities to adhere and form biofilm in the presence of divalent ions as shown in Figure 2. Calcium inhibited the adhesion of C. acnes ATCC 6919 to polystyrene approximately by 1.5 times in all tested concentrations (0.1, 1.0 and 10 mM). While the presence of 0.1 and 1 mM Mg2+ and Zn2+cations in the LB medium did not result in the significant inhibition of the adhesion of bacterial cells. The presence of Mg2+ and Zn2+ at concentrations in 10 and 100 times, respectively, higher than their serum levels caused almost 2 fold decrease in the number of attached cells compared to the control. The elongation of the incubation to 48 h resulted in a bit different result outcome, so the biomass of C. acnes biofilm was significantly lower than control only in the medium supplemented with zinc ions (Figure 2B). Moreover, the inhibitory effect of 1 mM and 10 mM Zn2+ was similar and the biofilm formation was diminished by 50%. In contrast to zinc, magnesium and calcium ions did not appear to have any effect on the biofilm formation of C. acnes.
Figure 2. Adhesion (A) and biofilm formation (B) of C. acnes ATCC 6919 on polystyrene surface in LB medium supplemented with 0.1, 1 and 10 mM of CaCl2, MgCl2 or ZnCl2.Thus, we found that calcium at the concentration in the range of normal level in the blood (1.05-1.23 mM) had the greatest effect on the first stages of biofilm formation. We also observed the small deceleration in C. acnes adhesion in medium containing 1 mM Mg2+. Most likely, divalent cations, such as Mg2+ and Ca2+, can influence adhesion and biofilm formation directly via non-specific electro-static interactions [24] and indirectly via physiology-dependent attachment processes by acting as important cellular cations and enzyme cofactors [15,16]. The presence of Zn2+ at non-bactericidal concentrations in growth media can stimulate the S. aureus adhesion to abiotic surfaces via the activation of cell-cell adhesion [25], and vice versa, Zn2+ caused the decrease of adhesive properties of Streptococcus suis [17]. Unfortunately, the role of zinc in the adhesion and biofilm formation of C. acnes has been poorly studied, but Ozuguz et al. [26] have found that the plasma levels of zinc in all patients with acne vulgaris were decreased almost in two times and this finding correlates with acne severity. Thus, the decrease of zinc concentration in blood plasma can lead to the development of C. acnes biofilm. Furthermore, in the light of these data we suggest that the effect of zinc-containing drugs used for the prevention and treatment of acne can be mediated not only by the regulation of the activity of sebaceous glands via the testosterone production [27], but also bound with the inhibitory activity of zinc against C. acnes adhesion and biofilm formation.
Hemagglutination of erythrocytes by microbes was often used as a marker of bacterial pathogenicity [18]. There was found that the ability of S. epidermidis to hemagglutinate erythrocytes correlated with the bacterial adherence to intravenous catheters [21]. In relation to C. acnes ATCC 6919, only their ability to internalize in osteoblasts and osteoclasts and survive intracellularly for at least 96 h has recently been shown [28]. Therefore, we evaluated the possibility of binding C. acnes cells with human erythrocytes. In our experiments we observed the absence of binding of C. acnes ATCC 6919 cells with erythrocytes (Figure 3) or the formation of a precipitate in the well similar to dairy propionibacteria [29]. The fact that C. acnes did not bind to erythrocytes may be the additional evidence of the assumption about the priority colonization of blood-poor environments by C. acnes.
Figure 3. The absence of the adhesion of C. acnes ATCC 6919 to human erythrocytes (O, Rh+) after 2 h of the incubation (magnification ×1000).The results of our studies indicate the high sensitivity of the first stages of the C. acnes biofilm formation to the blood components. So, the protein-coated surface (albumin, plasma) that could be formed on the prostheses in human body becomes unfavorable for the adherence and the biofilm formation of C. acnes. In addition, calcium and zinc can cause the decrease of C. acnes attachment. Therefore, the bacterial adhesion on the polystyrene depends on proteins and cations presenting in human blood. Thus, the results of this study confirm that bacteria C. acnes preferably colonize the plasma-poor environment due to the inhibitory effect of albumin, calcium and zinc.
All authors declare no conflicts of interest in this paper.
| [1] |
Gooley AA, Classon BJ, Marschalek R, et al. (1991) Glycosylation sites identified by detection of glycosylated amino acids released from Edman degradation: the identification of Xaa-Pro-Xaa-Xaa as a motif for Thr-O-glycosylation. Biochem Biophys Res Commun 178: 1194-1201. doi: 10.1016/0006-291X(91)91019-9
|
| [2] |
Yoshida A, Suzuki M, Ikenaga H, et al. (1997) Discovery of the shortest sequence motif for high level mucin-type O-glycosylation. J Biol Chem 272: 16884-16888. doi: 10.1074/jbc.272.27.16884
|
| [3] |
Young JD, Tsuchiya D, Sandlin DE, et al. (1979) Enzymic O-glycosylation of synthetic peptides from sequences in basic myelin protein. Biochemistry 18: 4444-4448. doi: 10.1021/bi00587a026
|
| [4] | Wilson IB, Gavel Y, von Heijne G (1991) Amino acid distributions around O-linked glycosylation sites. Biochem J 275 (Pt 2): 529-534. |
| [5] | Elhammer AP, Poorman RA, Brown E, et al. (1993) The specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase as inferred from a database of in vivo substrates and from the in vitro glycosylation of proteins and peptides. J Biol Chem 268: 10029-10038. |
| [6] |
Elliott S, Bartley T, Delorme E, et al. (1994) Structural requirements for addition of O-linked carbohydrate to recombinant erythropoietin. Biochemistry 33: 11237-11245. doi: 10.1021/bi00203a020
|
| [7] |
O'Connell B, Tabak LA, Ramasubbu N (1991) The influence of flanking sequences on O-glycosylation. Biochem Biophys Res Commun 180: 1024-1030. doi: 10.1016/S0006-291X(05)81168-4
|
| [8] |
Lehle L BE (1984) Primary structural requirements for N- and O-glycosylation of yeast mannoproteins. Biochim Biophys Acta 799: 246-251. doi: 10.1016/0304-4165(84)90267-8
|
| [9] |
Ladenson RP, Schwartz SO, Ivy AC (1949) Incidence of the blood groups and the secretor factor in patients with pernicious anemia and stomach carcinoma. Am J Med Sci 217: 194-197. doi: 10.1097/00000441-194902000-00011
|
| [10] |
Hakomori SI, Murakami WT (1968) Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines. Proc Natl Acad Sci U S A 59: 254-261. doi: 10.1073/pnas.59.1.254
|
| [11] |
Hakomori S (2002) Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 99: 10231-10233. doi: 10.1073/pnas.172380699
|
| [12] |
Reis CA, Osorio H, Silva L, et al. (2010) Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol 63: 322-329. doi: 10.1136/jcp.2009.071035
|
| [13] |
Ma Z, Vosseller K (2014) Cancer metabolism and elevated O-GlcNAc in oncogenic signaling. J Biol Chem 289: 34457-34465. doi: 10.1074/jbc.R114.577718
|
| [14] |
Fuster MM, Esko JD (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5: 526-542. doi: 10.1038/nrc1649
|
| [15] |
Kandoth C, McLellan MD, Vandin F, et al. (2013) Mutational landscape and significance across 12 major cancer types. Nature 502: 333-339. doi: 10.1038/nature12634
|
| [16] |
Anwar A, Norris DA, Fujita M (2011) Ubiquitin proteasomal pathway mediated degradation of p53 in melanoma. Arch Biochem Biophys 508: 198-203. doi: 10.1016/j.abb.2010.12.012
|
| [17] |
Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604. doi: 10.1038/nrc864
|
| [18] |
Riley T, Sontag E, Chen P, et al. (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402-412. doi: 10.1038/nrm2395
|
| [19] |
Vousden KH, Prives C (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137: 413-431. doi: 10.1016/j.cell.2009.04.037
|
| [20] |
Yang WH, Kim JE, Nam HW, et al. (2006) Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol 8: 1074-1083. doi: 10.1038/ncb1470
|
| [21] | Shaw P, Freeman J, Bovey R, et al. (1996) Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12: 921-930. |
| [22] |
Ito A, Lai CH, Zhao X, et al. (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20: 1331-1340. doi: 10.1093/emboj/20.6.1331
|
| [23] |
Rodriguez MS, Desterro JM, Lain S, et al. (2000) Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 20: 8458-8467. doi: 10.1128/MCB.20.22.8458-8467.2000
|
| [24] |
Chuikov S, Kurash JK, Wilson JR, et al. (2004) Regulation of p53 activity through lysine methylation. Nature 432: 353-360. doi: 10.1038/nature03117
|
| [25] |
Haupt Y, Maya R, Kazaz A, et al. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299. doi: 10.1038/387296a0
|
| [26] |
Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303. doi: 10.1038/387299a0
|
| [27] |
Bode AM, Dong Z (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805. doi: 10.1038/nrc1455
|
| [28] |
Bech-Otschir D, Kraft R, Huang X, et al. (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 20: 1630-1639. doi: 10.1093/emboj/20.7.1630
|
| [29] |
Liu K, Paterson AJ, Zhang F, et al. (2004) Accumulation of protein O-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high O-GlcNAc metabolism. J Neurochem 89: 1044-1055. doi: 10.1111/j.1471-4159.2004.02389.x
|
| [30] | Muller PA, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15: 2-8. |
| [31] |
Gaiddon C, Lokshin M, Ahn J, et al. (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21: 1874-1887. doi: 10.1128/MCB.21.5.1874-1887.2001
|
| [32] |
Strano S, Munarriz E, Rossi M, et al. (2000) Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 275: 29503-29512. doi: 10.1074/jbc.M003360200
|
| [33] |
Bian YS, Osterheld MC, Bosman FT, et al. (2001) p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol 14: 397-403. doi: 10.1038/modpathol.3880324
|
| [34] |
Maehama T, Dixon JE. (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378. doi: 10.1074/jbc.273.22.13375
|
| [35] |
Maehama T, Taylor GS, Dixon JE (2001) PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem 70: 247-279. doi: 10.1146/annurev.biochem.70.1.247
|
| [36] | Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619. |
| [37] |
Trotman LC, Wang X, Alimonti A, et al. (2007) Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128: 141-156. doi: 10.1016/j.cell.2006.11.040
|
| [38] |
Gong L, Govan JM, Evans EB, et al. (2015) Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. Cell Cycle 14: 2323-2332. doi: 10.1080/15384101.2015.1044174
|
| [39] |
Shi Y, Paluch BE, Wang X, et al. (2012) PTEN at a glance. J Cell Sci 125: 4687-4692. doi: 10.1242/jcs.093765
|
| [40] | Bermudez Brito M, Goulielmaki E, Papakonstanti EA (2015) Focus on PTEN Regulation. Front Oncol 5: 166. |
| [41] |
Hopkins BD, Fine B, Steinbach N, et al. (2013) A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science 341: 399-402. doi: 10.1126/science.1234907
|
| [42] |
Wang X, Trotman LC, Koppie T, et al. (2007) NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-139. doi: 10.1016/j.cell.2006.11.039
|
| [43] |
Vazquez F, Ramaswamy S, Nakamura N, et al. (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20: 5010-5018. doi: 10.1128/MCB.20.14.5010-5018.2000
|
| [44] | Torres J, Pulido R (2001) The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 276: 993-998. |
| [45] | Tolkacheva T, Boddapati M, Sanfiz A, et al. (2001) Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res 61: 4985-4989. |
| [46] |
Vazquez F, Grossman SR, Takahashi Y, et al. (2001) Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 276: 48627-48630. doi: 10.1074/jbc.C100556200
|
| [47] |
Das S, Dixon JE, Cho W (2003) Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci U S A 100: 7491-7496. doi: 10.1073/pnas.0932835100
|
| [48] |
Vazquez F, Matsuoka S, Sellers WR, et al. (2006) Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proc Natl Acad Sci U S A 103: 3633-3638. doi: 10.1073/pnas.0510570103
|
| [49] |
Maccario H, Perera NM, Davidson L, et al. (2007) PTEN is destabilized by phosphorylation on Thr366. Biochem J 405: 439-444. doi: 10.1042/BJ20061837
|
| [50] |
Xu D, Yao Y, Jiang X, et al. (2010) Regulation of PTEN stability and activity by Plk3. J Biol Chem 285: 39935-39942. doi: 10.1074/jbc.M110.166462
|
| [51] |
Gil A, Andres-Pons A, Fernandez E, et al. (2006) Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell 17: 4002-4013. doi: 10.1091/mbc.E06-05-0380
|
| [52] |
Ding L, Chen S, Liu P, et al. (2014) CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy. Cancer Res 74: 2050-2061. doi: 10.1158/0008-5472.CAN-13-1659
|
| [53] |
Wang Z, Pandey A, Hart GW (2007) Dynamic interplay between O-linked N-acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. Mol Cell Proteomics 6: 1365-1379. doi: 10.1074/mcp.M600453-MCP200
|
| [54] |
Zeidan Q, Hart GW (2010) The intersections between O-GlcNAcylation and phosphorylation: implications for multiple signaling pathways. J Cell Sci 123: 13-22. doi: 10.1242/jcs.053678
|
| [55] |
Wang Z, Gucek M, Hart GW (2008) Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc Natl Acad Sci U S A 105: 13793-13798. doi: 10.1073/pnas.0806216105
|
| [56] |
Waite KA, Eng C (2002) Protean PTEN: form and function. Am J Hum Genet 70: 829-844. doi: 10.1086/340026
|
| [57] | Han SY, Kato H, Kato S, et al. (2000) Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 60: 3147-3151. |
| [58] |
Georgescu MM, Kirsch KH, Akagi T, et al. (1999) The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A 96: 10182-10187. doi: 10.1073/pnas.96.18.10182
|
| [59] | Zhao Y, Huang Q, Wang A, et al. (2009) Mutation of PTEN in glioma stem/progenitor cells: a case report. Cancer Genet Cytogenet 195: 183-185. |
| [60] | Fan X, Munoz J, Sanko SG, et al. (2002) PTEN, DMBT1, and p16 alterations in diffusely infiltrating astrocytomas. Int J Oncol 21: 667-674. |
| [61] | Trigka EA, Levidou G, Saetta AA, et al. (2013) A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol Rep 30: 623-636. |
| [62] |
Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068. doi: 10.1038/nature07385
|
| [63] |
Cancer Genome Atlas Research N (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615. doi: 10.1038/nature10166
|
| [64] |
Wallace MD, Pfefferle AD, Shen L, et al. (2012) Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. Genetics 192: 385-396. doi: 10.1534/genetics.112.142802
|
| [65] |
Ding L, Getz G, Wheeler DA, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075. doi: 10.1038/nature07423
|
| [66] |
Boudry-Labis E, Roche-Lestienne C, Nibourel O, et al. (2013) Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia. Am J Hematol 88: 306-311. doi: 10.1002/ajh.23403
|
| [67] |
Martin GA, Viskochil D, Bollag G, et al. (1990) The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63: 843-849. doi: 10.1016/0092-8674(90)90150-D
|
| [68] | Xu GF, Lin B, Tanaka K, et al. (1990) The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63: 835-841. |
| [69] |
Izawa I, Tamaki N, Saya H (1996) Phosphorylation of neurofibromatosis type 1 gene product (neurofibromin) by cAMP-dependent protein kinase. FEBS Lett 382: 53-59. doi: 10.1016/0014-5793(96)00137-8
|
| [70] |
Feng L, Yunoue S, Tokuo H, et al. (2004) PKA phosphorylation and 14-3-3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin. FEBS Lett 557: 275-282. doi: 10.1016/S0014-5793(03)01507-2
|
| [71] |
Nasir ud D, Kaleem A, Ahmad I, et al. (2009) Effect on the Ras/Raf signaling pathway of post-translational modifications of neurofibromin: in silico study of protein modification responsible for regulatory pathways. J Cell Biochem 108: 816-824. doi: 10.1002/jcb.22301
|
| [72] |
Griffith LS, Schmitz B. (1999) O-linked N-acetylglucosamine levels in cerebellar neurons respond reciprocally to pertubations of phosphorylation. Eur J Biochem 262: 824-831. doi: 10.1046/j.1432-1327.1999.00439.x
|
| [73] |
Mangoura D, Sun Y, Li C, et al. (2006) Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. Oncogene 25: 735-745. doi: 10.1038/sj.onc.1209113
|
| [74] |
Leondaritis G, Petrikkos L, Mangoura D (2009) Regulation of the Ras-GTPase activating protein neurofibromin by C-tail phosphorylation: implications for protein kinase C/Ras/extracellular signal-regulated kinase 1/2 pathway signaling and neuronal differentiation. J Neurochem 109: 573-583. doi: 10.1111/j.1471-4159.2009.05975.x
|
| [75] | Kaufmann D, Junge I, Bartelt B, et al. (1999) On the lysosomal degradation of neurofibromin and its phosphorylation in cultured melanocytes. Biol Chem 380: 1071-1078. |
| [76] |
Perlman SL, Boder Deceased E, Sedgewick RP, et al. (2012) Ataxia-telangiectasia. Handb Clin Neurol 103: 307-332. doi: 10.1016/B978-0-444-51892-7.00019-X
|
| [77] |
McKinnon PJ (2012) ATM and the molecular pathogenesis of ataxia telangiectasia. Annu Rev Pathol 7: 303-321. doi: 10.1146/annurev-pathol-011811-132509
|
| [78] |
Shiloh Y, Ziv Y (2013) The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nature reviews Molecular cell biology 14: 197-210. doi: 10.1038/nrm3546
|
| [79] |
Ahmed M, Rahman N (2006) ATM and breast cancer susceptibility. Oncogene 25: 5906-5911. doi: 10.1038/sj.onc.1209873
|
| [80] | Swift M, Morrell D, Cromartie E, et al. (1986) The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 39: 573-583. |
| [81] |
Renwick A, Thompson D, Seal S, et al. (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38: 873-875. doi: 10.1038/ng1837
|
| [82] | Morrell D, Cromartie E, Swift M (1986) Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 77: 89-92. |
| [83] |
Abraham RT (2004) PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. DNA Repair (Amst) 3: 883-887. doi: 10.1016/j.dnarep.2004.04.002
|
| [84] |
Paull TT (2015) Mechanisms of ATM Activation. Annu Rev Biochem 84: 711-738. doi: 10.1146/annurev-biochem-060614-034335
|
| [85] | Jung M, Kondratyev A, Lee SA, et al. (1997) ATM gene product phosphorylates I kappa B-alpha. Cancer Res 57: 24-27. |
| [86] |
Li S, Ting NS, Zheng L, et al. (2000) Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 406: 210-215. doi: 10.1038/35018134
|
| [87] |
Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421: 499-506. doi: 10.1038/nature01368
|
| [88] |
Sun Y, Xu Y, Roy K, et al. (2007) DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol Cell Biol 27: 8502-8509. doi: 10.1128/MCB.01382-07
|
| [89] |
Kozlov SV, Graham ME, Jakob B, et al. (2011) Autophosphorylation and ATM activation: additional sites add to the complexity. J Biol Chem 286: 9107-9119. doi: 10.1074/jbc.M110.204065
|
| [90] |
Miura Y, Sakurai Y, Endo T (2012) O-GlcNAc modification affects the ATM-mediated DNA damage response. Biochim Biophys Acta 1820: 1678-1685. doi: 10.1016/j.bbagen.2012.06.013
|
| [91] |
Zhong J, Martinez M, Sengupta S, et al. (2015) Quantitative phosphoproteomics reveals crosstalk between phosphorylation and O-GlcNAc in the DNA damage response pathway. Proteomics 15: 591-607. doi: 10.1002/pmic.201400339
|
| [92] | Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265-271. |
| [93] | Schubert EL, Lee MK, Mefford HC, et al. (1997) BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60: 1031-1040. |
| [94] |
Hennessy BT, Timms KM, Carey MS, et al. (2010) Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clinic Oncology offic J Am Soc Clin Oncology 28: 3570-3576. doi: 10.1200/JCO.2009.27.2997
|
| [95] |
Gonzalez-Angulo AM, Timms KM, Liu S, et al. (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17: 1082-1089. doi: 10.1158/1078-0432.CCR-10-2560
|
| [96] |
Huen MS, Sy SM, Chen J (2010) BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Molecular Cell Biology 11: 138-148. doi: 10.1038/nrm2831
|
| [97] |
Rahman N, Stratton MR (1998) The genetics of breast cancer susceptibility. Annu Rev Genet 32: 95-121. doi: 10.1146/annurev.genet.32.1.95
|
| [98] |
Kleiman FE, Manley JL (2001) The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression. Cell 104: 743-753. doi: 10.1016/S0092-8674(01)00270-7
|
| [99] |
Welcsh PL, King MC (2001) BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10: 705-713. doi: 10.1093/hmg/10.7.705
|
| [100] |
Chen PL, Chen CF, Chen Y, et al. (1998) The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 95: 5287-5292. doi: 10.1073/pnas.95.9.5287
|
| [101] |
Savage KI, Harkin DP (2015) BRCA1, a 'complex' protein involved in the maintenance of genomic stability. FEBS J 282: 630-646. doi: 10.1111/febs.13150
|
| [102] |
Tram E, Savas S, Ozcelik H (2013) Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2. PLoS One 8: e62468. doi: 10.1371/journal.pone.0062468
|
| [103] | Jensen RA TM, Jetton TL, Szabo CI, et al. (1996) BRCA1 is secreted and exhibits properties of a granin. Nature 12: 303-308. |
| [104] |
Whelan SA, Lu M, He J, et al. (2009) Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers. J Proteome Res 8: 4151-4160. doi: 10.1021/pr900322g
|
| [105] |
Scully R, Chen J, Plug A, et al. (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88: 265-275. doi: 10.1016/S0092-8674(00)81847-4
|
| [106] | Siddique H, Rao VN, Reddy ES (2009) CBP-mediated post-translational N-glycosylation of BRCA2. Int J Oncol 35: 387-391. |
| [107] |
Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2: 103-112. doi: 10.1016/S1535-6108(02)00102-2
|
| [108] |
Di Fiore R, D'Anneo A, Tesoriere G, et al. (2013) RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J Cell Physiol 228: 1676-1687. doi: 10.1002/jcp.24329
|
| [109] |
Liu H, Dibling B, Spike B, et al. (2004) New roles for the RB tumor suppressor protein. Curr Opin Genet Dev 14: 55-64. doi: 10.1016/j.gde.2003.11.005
|
| [110] |
Giacinti C, Giordano A (2006) RB and cell cycle progression. Oncogene 25: 5220-5227. doi: 10.1038/sj.onc.1209615
|
| [111] |
Dowdy SF, Hinds PW, Louie K, et al. (1993) Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73: 499-511. doi: 10.1016/0092-8674(93)90137-F
|
| [112] |
De Luca A, MacLachlan TK, Bagella L, et al. (1997) A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity. J Biol Chem 272: 20971-20974. doi: 10.1074/jbc.272.34.20971
|
| [113] | Chan HM, La Thangue NB (2001) p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114: 2363-2373. |
| [114] |
Carr SM, Munro S, Kessler B, et al. (2011) Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO J 30: 317-327. doi: 10.1038/emboj.2010.311
|
| [115] |
Ledl A, Schmidt D, Muller S (2005) Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene 24: 3810-3818. doi: 10.1038/sj.onc.1208539
|
| [116] |
Wells L, Slawson C, Hart GW (2011) The E2F-1 associated retinoblastoma-susceptibility gene product is modified by O-GlcNAc. Amino Acids 40: 877-883. doi: 10.1007/s00726-010-0709-x
|
| [117] |
Delston RB, Matatall KA, Sun Y, et al. (2011) p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosis. Oncogene 30: 588-599. doi: 10.1038/onc.2010.442
|
| [118] |
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137. doi: 10.1038/35052073
|
| [119] |
Contessa JN, Bhojani MS, Freeze HH, et al. (2008) Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res 68: 3803-3809. doi: 10.1158/0008-5472.CAN-07-6389
|
| [120] | Soderquist AM, Carpenter G (1984) Glycosylation of the epidermal growth factor receptor in A-431 cells. The contribution of carbohydrate to receptor function. J Biol Chem 259: 12586-12594. |
| [121] | Slieker LJ, Martensen TM, Lane MD (1986) Synthesis of epidermal growth factor receptor in human A431 cells. Glycosylation-dependent acquisition of ligand binding activity occurs post-translationally in the endoplasmic reticulum. J Biol Chem 261: 15233-15241. |
| [122] |
Yokoe S, Takahashi M, Asahi M, et al. (2007) The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion. Cancer Res 67: 1935-1942. doi: 10.1158/0008-5472.CAN-06-3023
|
| [123] | Tsuda T, Ikeda Y, Taniguchi N (2000) The Asn-420-linked sugar chain in human epidermal growth factor receptor suppresses ligand-independent spontaneous oligomerization. Possible role of a specific sugar chain in controllable receptor activation. J Biol Chem 275: 21988-21994. |
| [124] |
Fernandes H, Cohen S, Bishayee S (2001) Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells. J Biol Chem 276: 5375-5383. doi: 10.1074/jbc.M005599200
|
| [125] | Ekstrand AJ, Liu L, He J, et al. (1995) Altered subcellular location of an activated and tumour-associated epidermal growth factor receptor. Oncogene 10: 1455-1460. |
| [126] | Moscatello DK, Montgomery RB, Sundareshan P, et al. (1996) Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13: 85-96. |
| [127] |
Nishikawa R, Ji XD, Harmon RC, et al. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91: 7727-7731. doi: 10.1073/pnas.91.16.7727
|
| [128] |
Humphrey PA, Gangarosa LM, Wong AJ, et al. (1991) Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem Biophys Res Commun 178: 1413-1420. doi: 10.1016/0006-291X(91)91051-D
|
| [129] |
Saxon ML, Lee DC (1999) Mutagenesis reveals a role for epidermal growth factor receptor extracellular subdomain IV in ligand binding. J Biol Chem 274: 28356-28362. doi: 10.1074/jbc.274.40.28356
|
| [130] |
Domagala T, Konstantopoulos N, Smyth F, et al. (2000) Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor. Growth factors 18: 11-29. doi: 10.3109/08977190009003231
|
| [131] |
Elleman TC, Domagala T, McKern NM, et al. (2001) Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry 40: 8930-8939. doi: 10.1021/bi010037b
|
| [132] |
Whitson KB, Whitson SR, Red-Brewer ML, et al. (2005) Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor. Biochemistry 44: 14920-14931. doi: 10.1021/bi050751j
|
| [133] |
Yoon SJ, Nakayama K, Hikita T, et al. (2006) Epidermal growth factor receptor tyrosine kinase is modulated by GM3 interaction with N-linked GlcNAc termini of the receptor. Proc Natl Acad Sci U S A 103: 18987-18991. doi: 10.1073/pnas.0609281103
|
| [134] |
Wakshull EM, Wharton W (1985) Stabilized complexes of epidermal growth factor and its receptor on the cell surface stimulate RNA synthesis but not mitogenesis. Proc Natl Acad Sci U S A 82: 8513-8517. doi: 10.1073/pnas.82.24.8513
|
| [135] |
Hirabayashi J, Hashidate T, Arata Y, et al. (2002) Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 1572: 232-254. doi: 10.1016/S0304-4165(02)00311-2
|
| [136] |
Partridge EA, Le Roy C, Di Guglielmo GM, et al. (2004) Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306: 120-124. doi: 10.1126/science.1102109
|
| [137] |
Lajoie P, Partridge EA, Guay G, et al. (2007) Plasma membrane domain organization regulates EGFR signaling in tumor cells. J Cell Biol 179: 341-356. doi: 10.1083/jcb.200611106
|
| [138] |
Guo HB, Johnson H, Randolph M, et al. (2009) Knockdown of GnT-Va expression inhibits ligand-induced downregulation of the epidermal growth factor receptor and intracellular signaling by inhibiting receptor endocytosis. Glycobiology 19: 547-559. doi: 10.1093/glycob/cwp023
|
| [139] |
Guo HB, Randolph M, Pierce M (2007) Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes: inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase. J Biol Chem 282: 22150-22162. doi: 10.1074/jbc.M611518200
|
| [140] | Guo P, Wang QY, Guo HB, et al. (2004) N-acetylglucosaminyltransferase V modifies the signaling pathway of epidermal growth factor receptor. Cell Mol Life Sci 61: 1795-1804. |
| [141] |
Guo H, Nairn A, dela Rosa M, et al. (2012) Transcriptional regulation of the protocadherin beta cluster during Her-2 protein-induced mammary tumorigenesis results from altered N-glycan branching. J Biol Chem 287: 24941-24954. doi: 10.1074/jbc.M112.369355
|
| [142] |
Guo HB, Johnson H, Randolph M, et al. (2010) Specific posttranslational modification regulates early events in mammary carcinoma formation. Proc Natl Acad Sci U S A 107: 21116-21121. doi: 10.1073/pnas.1013405107
|
| [143] |
Liu YC, Yen HY, Chen CY, et al. (2011) Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci U S A 108: 11332-11337. doi: 10.1073/pnas.1107385108
|
| [144] |
Yen HY, Liu YC, Chen NY, et al. (2015) Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition. Proc Natl Acad Sci U S A 112: 6955-6960. doi: 10.1073/pnas.1507329112
|
| [145] |
Matsumoto K, Yokote H, Arao T, et al. (2008) N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci 99: 1611-1617. doi: 10.1111/j.1349-7006.2008.00847.x
|
| [146] |
Lin WL, Lin YS, Shi GY, et al. (2015) Lewisy promotes migration of oral cancer cells by glycosylation of epidermal growth factor receptor. PLoS One 10: e0120162. doi: 10.1371/journal.pone.0120162
|
| [147] |
Ling YH, Li T, Perez-Soler R, et al. (2009) Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. Cancer Chemotherapy Pharmacol 64: 539-548. doi: 10.1007/s00280-008-0902-8
|
| [148] |
Park JJ, Yi JY, Jin YB, et al. (2012) Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells. Biochem Pharmacol 83: 849-857. doi: 10.1016/j.bcp.2012.01.007
|
| [149] | Gan HK, Walker F, Burgess AW, et al. (2007) The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. J Biol Chem 282: 2840-2850. |
| [150] |
Sprung R, Nandi A, Chen Y, et al. (2005) Tagging-via-substrate strategy for probing O-GlcNAc modified proteins. J Proteome Res 4: 950-957. doi: 10.1021/pr050033j
|
| [151] |
Stateva SR, Villalobo A (2015) O-GlcNAcylation of the human epidermal growth factor receptor. Organ Biomol Chem 13: 8196-8204. doi: 10.1039/C5OB00443H
|
| [152] | Kaleem A, Ahmad I, Hoessli DC, et al. (2009) Epidermal growth factor receptors: function modulation by phosphorylation and glycosylation interplay. Mol Biol Rep 36: 631-639. |
| [153] |
Bao J, Alroy I, Waterman H, et al. (2000) Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome. J Biol Chem 275: 26178-26186. doi: 10.1074/jbc.M002367200
|
| [154] |
Feinmesser RL, Wicks SJ, Taverner CJ, et al. (1999) Ca2+/calmodulin-dependent kinase II phosphorylates the epidermal growth factor receptor on multiple sites in the cytoplasmic tail and serine 744 within the kinase domain to regulate signal generation. J Biol Chem 274: 16168-16173. doi: 10.1074/jbc.274.23.16168
|
| [155] | Countaway JL, Nairn AC, Davis RJ (1992) Mechanism of desensitization of the epidermal growth factor receptor protein-tyrosine kinase. J Biol Chem 267: 1129-1140. |
| [156] |
Jaiswal BS, Kljavin NM, Stawiski EW, et al. (2013) Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23: 603-617. doi: 10.1016/j.ccr.2013.04.012
|
| [157] |
Prickett TD, Agrawal NS, Wei X, et al. (2009) Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41: 1127-1132. doi: 10.1038/ng.438
|
| [158] |
Kurppa KJ, Denessiouk K, Johnson MS, et al. (2016) Activating ERBB4 mutations in non-small cell lung cancer. Oncogene 35: 1283-1291. doi: 10.1038/onc.2015.185
|
| [159] | Polakis P (2012) Wnt signaling in cancer. Cold Spring Harbor perspectives in biology 4. |
| [160] |
Liu C, Li Y, Semenov M, et al. (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108: 837-847. doi: 10.1016/S0092-8674(02)00685-2
|
| [161] |
Winer IS, Bommer GT, Gonik N, et al. (2006) Lysine residues Lys-19 and Lys-49 of beta-catenin regulate its levels and function in T cell factor transcriptional activation and neoplastic transformation. J Biol Chem 281: 26181-26187. doi: 10.1074/jbc.M604217200
|
| [162] |
Li VS, Ng SS, Boersema PJ, et al. (2012) Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 149: 1245-1256. doi: 10.1016/j.cell.2012.05.002
|
| [163] |
Gao C, Xiao G, Hu J (2014) Regulation of Wnt/beta-catenin signaling by posttranslational modifications. Cell Biosci 4: 13. doi: 10.1186/2045-3701-4-13
|
| [164] |
Zhu W, Leber B, Andrews DW (2001) Cytoplasmic O-glycosylation prevents cell surface transport of E-cadherin during apoptosis. EMBO J 20: 5999-6007. doi: 10.1093/emboj/20.21.5999
|
| [165] |
Sayat R, Leber B, Grubac V, et al. (2008) O-GlcNAc-glycosylation of beta-catenin regulates its nuclear localization and transcriptional activity. Experiment Cell Res 314: 2774-2787. doi: 10.1016/j.yexcr.2008.05.017
|
| [166] |
Olivier-Van Stichelen S, Dehennaut V, Buzy A, et al. (2014) O-GlcNAcylation stabilizes beta-catenin through direct competition with phosphorylation at threonine 41. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 28: 3325-3338. doi: 10.1096/fj.13-243535
|
| [167] |
Vosseller K, Wells L, Lane MD, et al. (2002) Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 99: 5313-5318. doi: 10.1073/pnas.072072399
|
| [168] |
Ha JR, Hao L, Venkateswaran G, et al. (2014) beta-catenin is O-GlcNAc glycosylated at Serine 23: implications for beta-catenin's subcellular localization and transactivator function. Experiment Cell Res 321: 153-166. doi: 10.1016/j.yexcr.2013.11.021
|
| [169] |
van Noort M, van de Wetering M, Clevers H (2002) Identification of two novel regulated serines in the N terminus of beta-catenin. Experiment Cell Res 276: 264-272. doi: 10.1006/excr.2002.5520
|
| [170] | Nhieu JT, Renard CA, Wei Y, et al. (1999) Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 155: 703-710. |
| [171] |
Mazumder R, Morampudi KS, Motwani M, et al. (2012) Proteome-wide analysis of single-nucleotide variations in the N-glycosylation sequon of human genes. PLoS One 7: e36212. doi: 10.1371/journal.pone.0036212
|
| [172] |
Karagiannis K, Simonyan V, Mazumder R (2013) SNVDis: a proteome-wide analysis service for evaluating nsSNVs in protein functional sites and pathways. Genom Proteom Bioinform 11: 122-126. doi: 10.1016/j.gpb.2012.10.003
|
| [173] |
Cole C, Krampis K, Karagiannis K, et al. (2014) Non-synonymous variations in cancer and their effects on the human proteome: workflow for NGS data biocuration and proteome-wide analysis of TCGA data. BMC Bioinform 15: 28. doi: 10.1186/1471-2105-15-28
|
| [174] | Wu TJ, Shamsaddini A, Pan Y, et al. (2014) A framework for organizing cancer-related variations from existing databases, publications and NGS data using a High-performance Integrated Virtual Environment (HIVE). Database J Biolog Database Curation 2014: bau022. |
| [175] |
Meany DL, Chan DW (2011) Aberrant glycosylation associated with enzymes as cancer biomarkers. Clinical Proteom 8: 7. doi: 10.1186/1559-0275-8-7
|
| [176] | Venkitachalam S, Revoredo L, Varadan V, et al. (2016) Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer. Sci Report 6: 23642. |
| [177] |
Tanizaki J, Ercan D, Capelletti M, et al. (2015) Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. Cancer Res 75: 3139-3146. doi: 10.1158/0008-5472.CAN-14-3771
|
| [178] |
Yang X, Ongusaha PP, Miles PD, et al. (2008) Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 451: 964-969. doi: 10.1038/nature06668
|
| [179] |
Federici M, Menghini R, Mauriello A, et al. (2002) Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106: 466-472. doi: 10.1161/01.CIR.0000023043.02648.51
|
| [180] |
Wang S, Huang X, Sun D, et al. (2012) Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates Akt signaling. PLoS One 7: e37427. doi: 10.1371/journal.pone.0037427
|
| [181] |
Licitra L, Suardi S, Bossi P, et al. (2004) Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22: 4901-4906. doi: 10.1200/JCO.2004.05.071
|
| [182] | Munirajan AK, Tutsumi-Ishii Y, Mohanprasad BK, et al. (1996) p53 gene mutations in oral carcinomas from India. Int J Cancer 66: 297-300. |
| [183] | Balz V, Scheckenbach K, Gotte K, et al. (2003) Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63: 1188-1191. |
| [184] |
[Hsu CH, Yang SA, Wang JY, et al. (1999) Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br J Cancer 80: 1080-1086. doi: 10.1038/sj.bjc.6690467
|
| [185] |
Saito T, Oda Y, Kawaguchi K, et al. (2003) PTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balanced translocations. Int J Cancer 104: 175-178. doi: 10.1002/ijc.10918
|
| [186] |
Crona J, Verdugo AD, Granberg D, et al. (2013) Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma. Endocr Connect 2: 104-111. doi: 10.1530/EC-13-0009
|
| [187] |
Beltrame L, Di Marino M, Fruscio R, et al. (2015) Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. Ann Oncol 26: 1363-1371. doi: 10.1093/annonc/mdv472.137
|
| [188] |
Ciriello G, Gatza ML, Beck AH, et al. (2015) Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 163: 506-519. doi: 10.1016/j.cell.2015.09.033
|
| [189] |
Papaemmanuil E, Gerstung M, Malcovati L, et al. (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122: 3616-3627; quiz 3699. doi: 10.1182/blood-2013-08-518886
|
| [190] |
Cancer Genome Atlas Research N, Kandoth C, Schultz N, et al. (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497: 67-73. doi: 10.1038/nature12113
|
| [191] |
Frattini V, Trifonov V, Chan JM, et al. (2013) The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45: 1141-1149. doi: 10.1038/ng.2734
|
| [192] |
George J, Lim JS, Jang SJ, et al. (2015) Comprehensive genomic profiles of small cell lung cancer. Nature 524: 47-53. doi: 10.1038/nature14664
|
| [193] |
Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507: 315-322. doi: 10.1038/nature12965
|
| [194] |
Dulak AM, Stojanov P, Peng S, et al. (2013) Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45: 478-486. doi: 10.1038/ng.2591
|
| [195] |
Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337. doi: 10.1038/nature11252
|
| [196] |
Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70. doi: 10.1038/nature11412
|
| [197] |
Pickering CR, Zhou JH, Lee JJ, et al. (2014) Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 20: 6582-6592. doi: 10.1158/1078-0432.CCR-14-1768
|
| [198] |
Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513: 202-209. doi: 10.1038/nature13480
|
| [199] | Giannakis M, Mu XJ, Shukla SA, et al. (2016) Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. |
| [200] | Quesada V, Conde L, Villamor N, et al. (2012) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44: 47-52. |
| [201] |
Zang ZJ, Cutcutache I, Poon SL, et al. (2012) Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44: 570-574. doi: 10.1038/ng.2246
|
| [202] |
Li YY, Hanna GJ, Laga AC, et al. (2015) Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res 21: 1447-1456. doi: 10.1158/1078-0432.CCR-14-1773
|
| [203] | Haruta M, Arai Y, Watanabe N, et al. (2012) Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children. Cancer Sci 103: 1129-1135. |
| [204] |
Laurent-Puig P, Legoix P, Bluteau O, et al. (2001) Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120: 1763-1773. doi: 10.1053/gast.2001.24798
|
| [205] |
Boyault S, Rickman DS, de Reynies A, et al. (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45: 42-52. doi: 10.1002/hep.21467
|
| [206] |
Kazakov DV, Sima R, Vanecek T, et al. (2009) Mutations in exon 3 of the CTNNB1 gene (beta-catenin gene) in cutaneous adnexal tumors. Am J Dermatopathol 31: 248-255. doi: 10.1097/DAD.0b013e318198922a
|
| [207] |
Lu LC, Shao YY, Lee YH, et al. (2014) beta-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma. Oncology 87: 159-166. doi: 10.1159/000362821
|
| [208] | Hongyo T, Hoshida Y, Nakatsuka S, et al. (2005) p53, K-ras, c-kit and beta-catenin gene mutations in sinonasal NK/T-cell lymphoma in Korea and Japan. Oncol Rep 13: 265-271. |
| [209] | Kurniawan AN, Hongyo T, Hardjolukito ES, et al. (2006) Gene mutation analysis of sinonasal lymphomas in Indonesia. Oncol Rep 15: 1257-1263. |
| [210] | Garcia-Rostan G, Tallini G, Herrero A, et al. (1999) Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 59: 1811-1815. |
| [211] | Sakamoto A, Oda Y, Adachi T, et al. (2002) Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma. Arch Pathol Lab Med 126: 1071-1078. |
| [212] |
Miyake T, Tanaka Y, Kato K, et al. (2006) Gene mutation analysis and immunohistochemical study of beta-catenin in odontogenic tumors. Pathol Int 56: 732-737. doi: 10.1111/j.1440-1827.2006.02039.x
|
| [213] |
Dutt A, Salvesen HB, Chen TH, et al. (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 105: 8713-8717. doi: 10.1073/pnas.0803379105
|
| [214] |
Aitken SJ, Presneau N, Kalimuthu S, et al. (2015) Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses. Virchows Arch 467: 203-210. doi: 10.1007/s00428-015-1765-0
|
| [215] |
Matsumoto T, Yamazaki M, Takahashi H, et al. (2015) Distinct beta-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas. Am J Clin Pathol 144: 452-463. doi: 10.1309/AJCPZ5T2POOFMQVN
|
| [216] |
Shibata T, Kokubu A, Miyamoto M, et al. (2011) Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol 178: 1395-1402. doi: 10.1016/j.ajpath.2010.12.011
|
| [217] |
Hara K, Saito T, Hayashi T, et al. (2015) A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix. Pathol Res Pract 211: 657-664. doi: 10.1016/j.prp.2015.06.004
|
| [218] |
Rogers HA, Miller S, Lowe J, et al. (2009) An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET). Br J Cancer 100: 1292-1302. doi: 10.1038/sj.bjc.6604979
|
| [219] |
Liu X, Qian Q, Xu P, et al. (2011) A novel conditionally replicating "armed" adenovirus selectively targeting gastrointestinal tumors with aberrant wnt signaling. Hum Gene Ther 22: 427-437. doi: 10.1089/hum.2010.128
|
| [220] |
Romero S, Szafranska J, Cabrera E, et al. (2012) Role of tumor-associated macrophages and angiogenesis in desmoid-type fibromatosis. Virchows Arch 461: 117-122. doi: 10.1007/s00428-012-1265-4
|
| [221] | Maiti S, Alam R, Amos CI, et al. (2000) Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 60: 6288-6292. |
| [222] |
Fukuzawa R, Heathcott RW, Sano M, et al. (2004) Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol 7: 125-137. doi: 10.1007/s10024-003-3023-8
|
| [223] |
Scott RH, Murray A, Baskcomb L, et al. (2012) Stratification of Wilms tumor by genetic and epigenetic analysis. Oncotarget 3: 327-335. doi: 10.18632/oncotarget.468
|
| [224] |
Shimizu Y, Ikeda S, Fujimori M, et al. (2002) Frequent alterations in the Wnt signaling pathway in colorectal cancer with microsatellite instability. Genes Chromosomes Cancer 33: 73-81. doi: 10.1002/gcc.1226
|
| [225] |
Cieply B, Zeng G, Proverbs-Singh T, et al. (2009) Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 49: 821-831. doi: 10.1002/hep.22695
|
| [226] |
Kawahara A, Harada H, Abe H, et al. (2011) Nuclear beta-catenin expression in basal cell adenomas of salivary gland. J Oral Pathol Med 40: 460-466. doi: 10.1111/j.1600-0714.2011.01010.x
|
| [227] | Mirabelli-Primdahl L, Gryfe R, Kim H, et al. (1999) Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59: 3346-3351. |
| [228] |
Saegusa M, Okayasu I (2001) Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 194: 59-67. doi: 10.1002/path.856
|
| [229] |
Schulze K, Imbeaud S, Letouze E, et al. (2015) Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47: 505-511. doi: 10.1038/ng.3252
|
| [230] |
Shinohara A, Yokoyama Y, Wan X, et al. (2001) Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin gene is frequent in the development of the neoplasm of the uterine cervix. Gynecol Oncol 82: 450-455. doi: 10.1006/gyno.2001.6298
|
| [231] |
Hodis E, Watson IR, Kryukov GV, et al. (2012) A landscape of driver mutations in melanoma. Cell 150: 251-263. doi: 10.1016/j.cell.2012.06.024
|
| [232] |
Groen RW, Oud ME, Schilder-Tol EJ, et al. (2008) Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res 68: 6969-6977. doi: 10.1158/0008-5472.CAN-08-1322
|
| 1. | Michael Harding, Patricia Nadworny, Brenton Buziak, Amin Omar, Greg Daniels, Jie Feng, Improved Methods for Treatment of Phytopathogenic Biofilms: Metallic Compounds as Anti-Bacterial Coatings and Fungicide Tank-Mix Partners, 2019, 24, 1420-3049, 2312, 10.3390/molecules24122312 | |
| 2. | Keren Demishtein, Ram Reifen, Moshe Shemesh, Antimicrobial Properties of Magnesium Open Opportunities to Develop Healthier Food, 2019, 11, 2072-6643, 2363, 10.3390/nu11102363 | |
| 3. | Debabrata Chowdhury, George S. Deepe, Kavitha Subramanian Vignesh, 2019, Chapter 4, 978-981-15-0556-0, 57, 10.1007/978-981-15-0557-7_4 | |
| 4. | Shih-Chun Yang, Chwan-Fwu Lin, Abdullah Alshetaili, Ibrahim A. Aljuffali, Min-Yu Chien, Jia-You Fang, Combining the dual antibacterial and regenerative activities of platelet-rich plasma with β-lactams to mitigate MRSA-infected skin wounds, 2023, 165, 07533322, 115017, 10.1016/j.biopha.2023.115017 | |
| 5. | Ming-Jun Tsai, Cheng-Yu Lin, Jiří Trousil, Calvin T Sung, Mei-Hua Lee, Jia-You Fang, Shih-Chun Yang, Proteinase K/Retinoic Acid-Loaded Cationic Liposomes as Multifunctional Anti-Acne Therapy to Disorganize Biofilm and Regulate Keratinocyte Proliferation, 2023, Volume 18, 1178-2013, 3879, 10.2147/IJN.S416966 | |
| 6. | Guilherme C. L. S. do Amaral, Mohamed A. Hassan, Luciana Saraiva, Laís Y. S. Nakao, Marinella Holzhausen, Zilson M. Malheiros, Bernal Stewart, Giuseppe A. Romito, Cristina C. Villar, The effect of a multicomponent oral care regimen on gingival inflammation: A randomized controlled clinical trial, 2023, 0022-3492, 10.1002/JPER.23-0361 | |
| 7. | Haiquan Zhu, Song Mao, Wei Li, Association between Cu/Zn/Iron/Ca/Mg levels and cerebral palsy: a pooled-analysis, 2023, 13, 2045-2322, 10.1038/s41598-023-45697-w | |
| 8. | Li-Chong Xu, Jennifer L. Booth, Matthew Lanza, Tugba Ozdemir, Amelia Huffer, Chen Chen, Asma Khursheed, Dongxiao Sun, Harry R. Allcock, Christopher A. Siedlecki, In Vitro and In Vivo Assessment of the Infection Resistance and Biocompatibility of Small-Molecule-Modified Polyurethane Biomaterials, 2024, 1944-8244, 10.1021/acsami.3c18231 | |
| 9. | Maya Rima, Christina Villeneuve-Faure, Marvine Soumbo, Fatima El Garah, Ludovic Pilloux, Christine Roques, Kremena Makasheva, Towards a better understanding of the effect of protein conditioning layers on microbial adhesion: a focused investigation of fibronectin and bovine serum albumin layers on SiO2 surfaces, 2024, 2047-4830, 10.1039/D4BM00099D |
Figures(2) / Tables(3)
Carman K.M. Ip, Jun Yin, Patrick K.S. Ng, Shiaw-Yih Lin, Gordon B. Mills. Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management[J]. AIMS Medical Science, 2016, 3(4): 386-416. doi: 10.3934/medsci.2016.4.386
DownLoad: 